BioSpace News Archive

G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that G1’s Chief Executive Officer Jack Bailey will participate in the Guggenheim Healthcare Talks: 2021 Oncology Day conference. The fireside chat will take place on February 11, 2021 at 2:00 PM ET.

– Pharmacodynamic results confirm localized exoIL-12 pharmacologic activity without systemic IL-12 exposure – – Plan to initiate multi-dose study in CTCL patients, with data anticipated by year-end 2021–

ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion therapy and critical care applications, today announced the time of its fourth quarter and fiscal year 2020 earnings release and conference call.

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® technology platform, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will participate in a virtual fireside chat at the Guggenheim Healthcare Talks 2021 Oncology Day on February 11th at 3:30 p.m. ET.

NKMax America, a biotechnology company harnessing the power of the body’s immune system through the development of Natural Killer cell therapies, announced the appointment of Stephen Chen, MBA to Chief Operating Officer.

Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that it has entered into a securities purchase agreement with life science institutional investment funds managed by Decheng Capital, to purchase 4,285,710 units (the “Units”) from Equillium,

Protara Therapeutics, Inc., a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, announced that management will present at two upcoming virtual investor conferences:

Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that an expanded access protocol (EAP) for Oxbryta® (voxelotor) in pediatric patients with sickle cell disease (SCD) has been initiated and is currently enrolling

The Centre for Addiction and Mental Health (CAMH) having conducted a rigorous procurement process for an enterprise wide referral management and central intake solution has selected Novari Health technology.

Just over one year since the first case of COVID-19 was reported in Canada, new data now reveals the far-reaching impact of the pandemic on cancer care.